Our study found that UC-MSCs can effectively inhibit the development of bacterial pneumonia, primarily by reducing the number of macrophages and neutrophils and inhibiting the secretion of inflammatory factors IL-1β, IL-6, and TNF-α, thereby suppressing in vivo inflammatory reactions. This evidence concerns the gene IL1B and bacterial pneumonia.